GlassScriptPhysician profile
Zhijin Chai
NPI 1760725410
$1,192.72
in general payments reported to CMS, 2019-2025
21 companies · $151 in 2025
The $151 reported for 2025 was less than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $140 · 2020: $129 · 2021: $101 · 2022: $299 · 2023: $89.86 · 2024: $283 · 2025: $151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $524.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $523.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $214.17 | 2019-2024 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $175.76 | 2021-2025 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $153.95 | 2022-2024 | Ofev |
| Electromed, INC. | $130.37 | 2019-2022 | |
| Insmed, INC. | $62.82 | 2019-2024 | Arikayce |
| Abiomed | $53.44 | 2022 | |
| La Jolla Pharmaceutical Company | $48.00 | 2020 | |
| Grifols USA, LLC | $44.54 | 2022-2023 | Prolastin-C Liquid |
| Bayer Healthcare Pharmaceuticals INC. | $39.13 | 2019-2022 | |
| Seagen INC. | $36.68 | 2020-2022 | |
| Genzyme Corporation | $33.69 | 2024 | |
| Harmony Biosciences LLC | $25.70 | 2024 | |
| Csl Behring | $24.59 | 2022 | |
| Avadel Cns Pharmaceuticals, LLC | $23.24 | 2024 | Lumryz |
| Regeneron Healthcare Solutions, INC. | $22.87 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $21.46 | 2024 | Uptravi, Opsumit |
| Amgen INC. | $18.99 | 2025 | Tezspire |
| Pfizer INC. | $17.83 | 2020 | |
| Olympus America INC. | $16.34 | 2022 | |
| Chiesi USA, INC. | $15.01 | 2020 | |
| Incyte Corporation | $14.14 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zhijin Chai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.